# Be Biopharma

> Be Biopharma (Be Bio) was a Cambridge, Massachusetts clinical-stage biotechnology company
> developing engineered B Cell Medicines (BCMs) — a patient's own B cells engineered to produce
> a therapeutic protein — for genetic disease, cancer and other serious conditions.
> It is a therapeutics developer, not a software company, and publishes no API.

<!--
generated: '2026-08-06'
method: generated
source: apis.yml (API Evangelist profile); provider publishes no llms.txt
-->

## What this is

This file is published by API Evangelist as part of an independent, third-party profile of
Be Biopharma. It is not authored or endorsed by the company.

## API surface

**None.** Be Biopharma has no public API, SDK, developer portal, webhook surface or
machine-readable contract, and no evidence of one was ever published:

- No `openapi.json`, `swagger.json`, GraphQL SDL, AsyncAPI or MCP endpoint on any company host.
- No `api.`, `dev.`, `developer.`, `docs.` or `portal.` subdomain has ever been archived for `be.bio`.
- Archived probes of `www.be.bio/.well-known/` (`security.txt`, `openid-configuration`,
  `ai-plugin.json`) returned 404.
- No GitHub organization; no first-party packages on npm, PyPI or RubyGems.

## Company status

As of 2026-08-06 the company's own domain `be.bio` no longer resolves — the authoritative
nameservers return SOA only for both the apex and `www`. The site was last archived on
2026-05-13. The company terminated its lead Phase 1/2 BeCoMe-9 trial of BE-101 in hemophilia B
in June 2026 for stated strategic business reasons.

## Background

- Founded October 2020 by Longwood Fund with David Rawlings, M.D. and Richard James, Ph.D.
  of Seattle Children's Research Institute.
- Lead program BE-101: a functional Factor IX gene inserted into primary human B cells for
  hemophilia B; FDA Orphan Drug and Fast Track designations.
- Second program BE-102: hypophosphatasia.
- Financing: $82M (October 2024); $92M Series C (January 2025).
- First participant dosed in BeCoMe-9, July 2025.

## Links

- Website (currently unresolvable): https://be.bio/
- Archived site: https://web.archive.org/web/20260513184102/https://be.bio/
- LinkedIn: https://www.linkedin.com/company/be-biopharma-inc
- Secondary-market listing: https://forgeglobal.com/be-biopharma_stock/

## Profile artifacts

- Domain security probe: security/be-biopharma-domain-security.yml
- Profile: apis.yml